University of Zurich's spin-off Invasight has developed the ACINDA platform that helps to identify signaling pathways causing cancer metastasis. As a result, Invasight has generated a pipeline of small molecules that will be used as anti-invasive drugs in cancer therapies. Invasight’s lead candidate F2i is in the stage of lead optimization before clinical trials. It is aimed at 22 cancers driven by the Fibroblast Growth Factor (FGF) aberrations. More specifically F2i will help patients with gastric cancer, the first market application where no approved drug currently exists for this specific pathway. With an innovative mode of action that has been confirmed by in-vivo studies, this drug candidate is highly effective and at the same time has a very favorable safety profile.
Wanted field of studies